A detailed history of Black Rock Inc. transactions in Chroma Dex Corp. stock. As of the latest transaction made, Black Rock Inc. holds 3,116,178 shares of CDXC stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,116,178
Previous 902,953 245.11%
Holding current value
$16.5 Million
Previous $3.14 Million 170.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.44 - $4.32 $5.4 Million - $9.56 Million
2,213,225 Added 245.11%
3,116,178 $8.51 Million
Q1 2024

May 10, 2024

SELL
$1.36 - $3.84 $2,365 - $6,677
-1,739 Reduced 0.19%
902,953 $3.14 Million
Q4 2023

Feb 13, 2024

SELL
$1.28 - $1.6 $3,595 - $4,494
-2,809 Reduced 0.31%
904,692 $1.29 Million
Q3 2023

Nov 13, 2023

SELL
$1.36 - $1.77 $8,591 - $11,181
-6,317 Reduced 0.69%
907,501 $1.32 Million
Q2 2023

Aug 11, 2023

BUY
$1.31 - $1.79 $16,534 - $22,593
12,622 Added 1.4%
913,818 $1.43 Million
Q1 2023

May 12, 2023

SELL
$1.48 - $2.19 $122,533 - $181,316
-82,793 Reduced 8.41%
901,196 $1.38 Million
Q4 2022

Feb 13, 2023

BUY
$1.25 - $1.94 $1,178 - $1,829
943 Added 0.1%
983,989 $1.65 Million
Q3 2022

Nov 14, 2022

SELL
$1.19 - $2.06 $6,953 - $12,036
-5,843 Reduced 0.59%
983,046 $1.21 Million
Q2 2022

Aug 12, 2022

SELL
$1.59 - $2.7 $3.44 Million - $5.85 Million
-2,164,820 Reduced 68.64%
988,889 $1.65 Million
Q1 2022

May 12, 2022

SELL
$2.02 - $3.92 $83,537 - $162,111
-41,355 Reduced 1.29%
3,153,709 $7.76 Million
Q4 2021

Feb 10, 2022

BUY
$3.74 - $6.7 $192,172 - $344,266
51,383 Added 1.63%
3,195,064 $12 Million
Q3 2021

Nov 09, 2021

BUY
$6.05 - $10.41 $151,697 - $261,020
25,074 Added 0.8%
3,143,681 $19.7 Million
Q2 2021

Aug 11, 2021

BUY
$6.66 - $10.92 $20.8 Million - $34.1 Million
3,118,607 New
3,118,607 $30.8 Million

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $362M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.